EU H2020 Project "GRI3D (The industrialization and market entry of a novel bioengineered hydrogel grid..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/214241/index.html
-1	/open-h2020/per-topic/factorize/list/index.html
-2	/open-h2020/projects/208951/index.html
-3	/open-h2020/projects/207509/index.html
-4	/open-h2020/projects/223875/index.html
-5	/open-h2020/projects/218546/index.html
-6	/open-h2020/projects/217717/index.html
-7	/open-h2020/projects/193771/index.html
-8	/open-fp7/projects/185605/index.html

Gri3D project word cloud

Explore the words cloud of the Gri3D project. It provides you a very rough idea of what is the project "Gri3D" about.

intention stem generate units standard recurrent leader health switzerland auomates microstructured practical line termed biocompatible organ economical bioscience clients 2021 tenth patient run microembossing verify pharmaceutical 3d handling viability spin sme epfl business move assays corresponds basic hydra possibilities machine hydrogel groups instrument feasibility cells entry gri3d producing 2m company total sa 600m off sun customers world technologies academic dish organoids models endless capacity translated medicine volume gt organoid maximum industrial diagnostics initiate cumulative customer clinical single first manufacturing 2016 introduction cultures platform validate care miniature successful founded ambition opened base tested commercializing annual strategy expand market industry revenues mechanism precision automated prototypes liquid

Project "Gri3D" data sheet

The following table provides information about the project.

Coordinator	SUN BIOSCIENCE SA Organization address address: EPFL INNOVATION PARK BATIMENT C city: LAUSANNE postcode: 1015 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Switzerland [CH]
Project website	http://www.sunbioscience.ch
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing) 2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-SMEINST-1-2016-2017
Funding Scheme	SME-1
Starting year	2018
Duration (year-month-day)	from 2018-03-01 to 2018-08-31

#	participants	country	role	EC contrib. [€]
1	SUN BIOSCIENCE SA	CH (LAUSANNE)	coordinator	50˙000.00

SUN BIOSCIENCE SA

CH (LAUSANNE)

coordinator

50˙000.00

Project objective

The ability to generate miniature organ models in a dish, termed organoids, from patient stem cells has opened endless possibilities for applications in precision medicine. SUN bioscience SA, a spin-off company of EPFL in Switzerland, was founded in 2016 with the ambition to move these organoid cultures from basic research to the Health Care industry.

To reach this goal, SUN bioscience has developed Gri3D, a microstructured biocompatible hydrogel platform, and aims to establish this technology as a new standard for growing organoids at industrial scale and precision. Gri3D prototypes have been field tested with over 30 European academic and pharmaceutical R&D groups. In addition, SUN bioscience has developed an industrial automated manufacturing mechanism for Gri3D that is now being translated into the world-wide first machine, Hydra I, that auomates liquid handling with hydrogel microembossing.

The objective of this feasibility study is to verify the technical, economical and practical viability of Gri3D and to ensure its successful market entry in Europe. Specifically, the first step is to validate the production capacity of Hydra I by producing 1’000 Gri3D units, which corresponds to one tenth of the total annual target production volume. In a second step, SUN bioscience aims to validate the market by commercializing these 1’000 Gri3D units to existing customers and to expand its customer base to a total of 20-40 recurrent clients.

According to our current strategy, SUN bioscience will run at maximum single line production capacity with cumulative revenues of >€2M within 3 years after market introduction of Gri3D. The 3D technologies market is expected to reach €600M by 2021. The long-term business objective is to implement organoid assays on Gri3D and to establish SUN bioscience as a leader in clinical diagnostics with the intention to initiate a phase 2 SME instrument project along this path.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GRI3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GRI3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)